应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
06855 亚盛医药-B
未开盘 07-04 16:09:02
27.350
+0.000
0.00%
最高
27.800
最低
26.800
成交量
108.91万
今开
27.650
昨收
27.350
日振幅
3.66%
总市值
86.06亿
流通市值
86.06亿
总股本
3.15亿
成交额
2,984万
换手率
0.35%
流通股本
3.15亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
亚盛医药(06855.HK)已向Takeda收取1亿美元独家选择权付款
阿斯达克财经 · 07-04 08:45
亚盛医药(06855.HK)已向Takeda收取1亿美元独家选择权付款
亚盛医药宣布已收到武田1亿美元选择权付款
美通社 · 07-04 08:39
亚盛医药宣布已收到武田1亿美元选择权付款
亚盛医药-B(06855):根据与Takeda订立的独家选择权协议已收取的选择权付款
智通财经 · 07-04 07:22
亚盛医药-B(06855):根据与Takeda订立的独家选择权协议已收取的选择权付款
亚盛医药-B(06855)上涨5.29%,报26.85元/股
金融界 · 07-03 13:09
亚盛医药-B(06855)上涨5.29%,报26.85元/股
亚盛医药-B盘中异动 股价大涨5.10%
自选股智能写手 · 07-03 13:09
亚盛医药-B盘中异动 股价大涨5.10%
亚盛医药-B(06855)股价上升5.098%,现价港币$26.8
阿斯达克财经 · 07-03 13:09
亚盛医药-B(06855)股价上升5.098%,现价港币$26.8
亚盛医药-B07月02日主力资金流入97万元 连续7日加仓
自选股智能写手 · 07-02 16:15
亚盛医药-B07月02日主力资金流入97万元 连续7日加仓
亚盛医药(6855.HK):三箭齐发 海外进展顺利
西南证券 · 06-26
亚盛医药(6855.HK):三箭齐发 海外进展顺利
亚盛医药-B06月26日获主力加仓81万元 环比增加350.00%
自选股智能写手 · 06-26
亚盛医药-B06月26日获主力加仓81万元 环比增加350.00%
亚盛医药-B06月25日主力资金流入18万元 连续3日加仓
自选股智能写手 · 06-25
亚盛医药-B06月25日主力资金流入18万元 连续3日加仓
亚盛医药:中国Biopharma国际化进阶样本
医药魔方 · 06-25
亚盛医药:中国Biopharma国际化进阶样本
出海创新仍为主线,港股创新药ETF(159567)跟踪指数趋势上行,康方生物、药明生物、亚盛医药-B领涨。
有连云 · 06-24
出海创新仍为主线,港股创新药ETF(159567)跟踪指数趋势上行,康方生物、药明生物、亚盛医药-B领涨。
亚盛医药宣布已收到武田7500万美元股权投资款项
美通社 · 06-21
亚盛医药宣布已收到武田7500万美元股权投资款项
【港股通】亚盛医药(06855)完成向Takeda International配发及发行2430.73万股
金吾财讯 · 06-21
【港股通】亚盛医药(06855)完成向Takeda International配发及发行2430.73万股
亚盛医药-B(06855)完成向Takeda International发行合共约2430.73万股认购股份
智通财经 · 06-21
亚盛医药-B(06855)完成向Takeda International发行合共约2430.73万股认购股份
拆解国产小分子BD第一案
钛媒体APP · 06-20
拆解国产小分子BD第一案
亚盛医药-B盘中异动 急速下跌5.11%
自选股智能写手 · 06-20
亚盛医药-B盘中异动 急速下跌5.11%
亚盛医药-B(06855)股价下跌5.114%,现价港币$25.05
阿斯达克财经 · 06-20
亚盛医药-B(06855)股价下跌5.114%,现价港币$25.05
亚盛医药-B06月19日主力资金流入226万元 连续5日加仓
自选股智能写手 · 06-19
亚盛医药-B06月19日主力资金流入226万元 连续5日加仓
【券商聚焦】东吴证券首予亚盛医药(06855)买入”评级 指奥雷巴替尼授权落地 全球创新步入收获期
金吾财讯 · 06-18
【券商聚焦】东吴证券首予亚盛医药(06855)买入”评级 指奥雷巴替尼授权落地 全球创新步入收获期
加载更多
公司概况
公司名称:
亚盛医药-B
所属市场:
SEHK
上市日期:
--
主营业务:
亚盛医药集团是一家主要从事开发癌症、乙型肝炎病毒及若干衰老相关疾病的创新微型疗法的投资控股公司。该公司拥有自主研发的蛋白-蛋白相互作用靶向药物设计平台。该公司的主要产品包括下一代激酶抑制剂HQP1351,细胞凋亡靶向药物APG-1252、 APG2575、APG-115等。该公司于国内市场及美国等海外市场开展业务。
发行价格:
--
{"stockData":{"symbol":"06855","market":"HK","secType":"STK","nameCN":"亚盛医药-B","latestPrice":27.35,"timestamp":1720080542020,"preClose":27.35,"halted":0,"volume":1089106,"delay":0,"floatShares":314653605,"shares":314653605,"eps":-3.5095327,"marketStatus":"未开盘","marketStatusCode":0,"change":0,"latestTime":"07-04 16:09:02","open":27.65,"high":27.8,"low":26.8,"amount":29842798,"amplitude":0.036563,"askPrice":27.35,"askSize":2200,"bidPrice":27.3,"bidSize":8900,"shortable":3,"etf":0,"ttmEps":-3.5095326787973447,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1720143000000},"adr":0,"listingDate":1572192000000,"adjPreClose":27.35,"openAndCloseTimeList":[[1720056600000,1720065600000],[1720069200000,1720080000000]],"volumeRatio":1.0703950662235373,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06855","defaultTab":"news","newsList":[{"id":"2448209450","title":"亚盛医药(06855.HK)已向Takeda收取1亿美元独家选择权付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2448209450","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448209450?lang=zh_cn&edition=full","pubTime":"2024-07-04 08:45","pubTimestamp":1720053900,"startTime":"0","endTime":"0","summary":"亚盛医药公布,根据与Takeda的耐立克独家选择权协议,已于7月2日收取Takeda的1亿美元选择权付款。耐立克为一种口服、潜在同类最佳的第三代BCR-ABL TKI,目前正在开发用于治疗CML及其他血液癌症。根据独家选择权协议,允许亚盛收取1亿美元的选择权付款,且倘Takeda行使选择权以许可耐立克,则让亚盛有资格获得最高约12亿美元的选择权行使费及额外的潜在里程碑付款,以及年销售额两位数百分比的销售分成。沽空资料截至 2024-07-03 16:25。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20201214152343086_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20201214152343086_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1361234/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09939","159938","BK1515","BK1574","06855","BK1161"],"gpt_icon":0},{"id":"2448450176","title":"亚盛医药宣布已收到武田1亿美元选择权付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2448450176","media":"美通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448450176?lang=zh_cn&edition=full","pubTime":"2024-07-04 08:39","pubTimestamp":1720053540,"startTime":"0","endTime":"0","summary":"2024年6月14日,亚盛医药宣布与武田签署了独家选择权协议,授予武田独家选择权以就耐立克签署独家许可协议。根据该独家选择权协议条款,亚盛医药可收取1亿美元的选择权付款,并将有资格获得最高约12亿美元的选择权行使费和额外的潜在里程碑付款,以及年销售额两位数百分比的销售分成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4454675_ZH54675_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1574","CDE","06855","BK4017","BK1161"],"gpt_icon":0},{"id":"2448451383","title":"亚盛医药-B(06855):根据与Takeda订立的独家选择权协议已收取的选择权付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2448451383","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448451383?lang=zh_cn&edition=full","pubTime":"2024-07-04 07:22","pubTimestamp":1720048927,"startTime":"0","endTime":"0","summary":"智通财经APP讯,亚盛医药-B 发布公告,内容有关公司、香港亚盛、广州亚盛、苏州亚盛及Takeda Pharmaceuticals International AG 订立独家选择权协议。独家选择权协议允许亚盛收取1亿美元的选择权付款,且倘 Takeda行使选择权以许可耐立克 ,则让亚盛有资格获得最高约12亿美元的选择权行使费及额外的潜在里程碑付款,以及年销售额两位数百分比的销售分成。公司董事会欣然宣布,亚盛已于2024年7月2日收取独家选择权协议条款允许的该选择权付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1145364.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","159938","06855","BK1161","09939","BK1574"],"gpt_icon":0},{"id":"2448123659","title":"亚盛医药-B(06855)上涨5.29%,报26.85元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448123659","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448123659?lang=zh_cn&edition=full","pubTime":"2024-07-03 13:09","pubTimestamp":1719983378,"startTime":"0","endTime":"0","summary":"7月3日,亚盛医药-B盘中上涨5.29%,截至13:09,报26.85元/股,成交2881.56万元。亚盛医药集团是一家专注于肿瘤、乙肝及与衰老相关疾病治疗领域的创新药物开发的生物医药企业,拥有自主构建的蛋白-蛋白相互作用靶向药物设计平台,并已建立9个已进入临床开发阶段的1类小分子新药产品管线。截至2023年年报,亚盛医药-B营业总收入2.22亿元、净利润-9.26亿元。7月2日,国元国际控股维持买入评级,目标价34.15港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/03130941343248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06855","BK1161","159938","BK1574","09939","BK1515"],"gpt_icon":0},{"id":"2448355125","title":"亚盛医药-B盘中异动 股价大涨5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2448355125","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448355125?lang=zh_cn&edition=full","pubTime":"2024-07-03 13:09","pubTimestamp":1719983373,"startTime":"0","endTime":"0","summary":"2024年07月03日下午盘13时09分,亚盛医药-B股票出现波动,股价快速上涨5.10%。截至发稿,该股报26.800港元/股,成交量109.87万股,换手率0.35%,振幅5.29%。亚盛医药-B股票所在的生物技术行业中,整体涨幅为0.34%。其相关个股中,东曜药业-B、荃信生物-B、永泰生物-B涨幅较大,振幅较大的相关个股有盛禾生物-B、药明巨诺-B、方达控股,振幅分别为19.28%、17.46%、8.22%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240703130933aef7b3b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240703130933aef7b3b5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06855","BK1515","BK1161","09939"],"gpt_icon":0},{"id":"2448123274","title":"亚盛医药-B(06855)股价上升5.098%,现价港币$26.8","url":"https://stock-news.laohu8.com/highlight/detail?id=2448123274","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448123274?lang=zh_cn&edition=full","pubTime":"2024-07-03 13:09","pubTimestamp":1719983340,"startTime":"0","endTime":"0","summary":"[上升股]亚盛医药-B(06855) 股价在下午01:09比前收市价上升5.098%,现股价为港币$26.8。至目前为止,今日最高价为$26.8,而最低价为$25.45。总成交量为108.26万股,总成交金额为港币$2.834千万。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2407032510/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09939","BK1161","BK1515","BK1574","06855","159938"],"gpt_icon":0},{"id":"2448184634","title":"亚盛医药-B07月02日主力资金流入97万元 连续7日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2448184634","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448184634?lang=zh_cn&edition=full","pubTime":"2024-07-02 16:15","pubTimestamp":1719908157,"startTime":"0","endTime":"0","summary":"07月02日, 亚盛医药-B股价跌0.20%,报收25.50元,成交金额2062万元,换手率0.26%,振幅2.94%,量比0.71。亚盛医药-B今日主力资金净流入97万元,连续7日净流入,上一交易日主力净流入292万元,今日环比减少66.78%。该股近5个交易日上涨1.60%,主力资金累计净流入736万元,其中2个交易日为股价下跌时净流入;近20日主力资金累计净流入3923万元,其中净流入天数为15日。该股主力净额占比0.01%,港股市场排名214/2640。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021616139ef317f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021616139ef317f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06855","BK1161","BK1574","09939","BK1515"],"gpt_icon":0},{"id":"2446365204","title":"亚盛医药(6855.HK):三箭齐发 海外进展顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=2446365204","media":"西南证券","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446365204?lang=zh_cn&edition=full","pubTime":"2024-06-26 18:41","pubTimestamp":1719398507,"startTime":"0","endTime":"0","summary":"事件:6月21 日,亚盛医药宣布已收到武田7500万美元股权投资款项。亚盛医药三箭齐发,耐立克授权、收到股权投资并计划赴美上市。将奥雷巴替尼除中国和其他一些地区之外的全球权利在全球范围内进行许可,亚盛医药在协议签署后将收到1 亿美元的选择权付款,并有资格获得最高约12 亿美元的选择权行使费和额外的潜在里程碑付款,以及基于年度销售额提成的双位数比例特许权使用费。APG-2575 国际化进程提速,多项适应症进入Ⅲ期临床。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406261841499f677df9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406261841499f677df9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","06855","BK1161","09939","BK1574"],"gpt_icon":0},{"id":"2446607355","title":"亚盛医药-B06月26日获主力加仓81万元 环比增加350.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2446607355","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446607355?lang=zh_cn&edition=full","pubTime":"2024-06-26 16:15","pubTimestamp":1719389725,"startTime":"0","endTime":"0","summary":"06月26日, 亚盛医药-B股价涨0.20%,报收25.35元,成交金额1132万元,换手率0.14%,振幅2.17%,量比0.25。亚盛医药-B今日主力资金净流入81万元,连续4日净流入,上一交易日主力净流入18万元,今日环比增加350.00%。近一年数据显示,该股主力连续4日净流入后,次日上涨概率为66.67%,平均涨幅为3.61%。该股近5个交易日下跌3.60%,主力资金累计净流入704万元;近20日主力资金累计净流入2583万元,其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062616154295d98ce1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062616154295d98ce1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06855","09939","BK1515","BK1161","BK1574"],"gpt_icon":0},{"id":"2446899483","title":"亚盛医药-B06月25日主力资金流入18万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2446899483","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446899483?lang=zh_cn&edition=full","pubTime":"2024-06-25 16:16","pubTimestamp":1719303413,"startTime":"0","endTime":"0","summary":"06月25日, 亚盛医药-B股价涨1.00%,报收25.30元,成交金额3757万元,换手率0.47%,振幅4.79%,量比0.67。亚盛医药-B今日主力资金净流入18万元,连续3日净流入,上一交易日主力净流入498万元,今日环比减少96.39%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为60.00%,平均涨幅为3.28%。该股近5个交易日下跌4.54%,主力资金累计净流入849万元;近20日主力资金累计净流入2353万元,其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406251617269f631967&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406251617269f631967&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06855","09939","BK1515","BK1161","BK1574"],"gpt_icon":0},{"id":"2446629839","title":"亚盛医药:中国Biopharma国际化进阶样本","url":"https://stock-news.laohu8.com/highlight/detail?id=2446629839","media":"医药魔方","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446629839?lang=zh_cn&edition=full","pubTime":"2024-06-25 07:55","pubTimestamp":1719273315,"startTime":"0","endTime":"0","summary":"6月14日,亚盛医药一连发出的三则公告,让业内和市场看到了一个更为进阶的中国Biopharma国际化样本。而如此强强联合,不仅让业界看到了一家中国Biopharma打造“十亿美元分子”的潜力及创新的价值,也预示着亚盛医药迈出了国际化的崭新一步。下一个重磅产品已箭在弦上于一家创新药企而言,首款上市产品的重要性不言而喻,它不仅是技术平台实力的验证,也是一家Biopharma发展潜力的体现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062508001795d455d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062508001795d455d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06855","BK1574","BK1515","09939","BK1161"],"gpt_icon":0},{"id":"2445048978","title":"出海创新仍为主线,港股创新药ETF(159567)跟踪指数趋势上行,康方生物、药明生物、亚盛医药-B领涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2445048978","media":"有连云","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445048978?lang=zh_cn&edition=full","pubTime":"2024-06-24 14:41","pubTimestamp":1719211305,"startTime":"0","endTime":"0","summary":"2024年6月24日,港股创新药板块趋势上行。盘面上,康方生物领涨,药明生物、亚盛医药-B跟涨,港股创新药ETF市场热度较高,过去5个交易日日均成交额达到6194万元。国内医药创新支持政策陆续出台,叠加美债利率下行预期,创新产业链有望迎来估值修复。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406241441469f5e99dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406241441469f5e99dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1720050803.USD","LU0359202008.SGD","LU0819121731.USD","LU1880383366.USD","LU0348825331.USD","LU0348735423.USD","LU0708995583.HKD","06855","LU0516422952.EUR","SG9999002463.SGD","LU0327786744.USD","LU0052750758.USD","BK1521","BK1161","IE00B0JY6N72.USD","LU0856984785.SGD","LU0307460666.USD","LU0417516571.SGD","LU0823426480.USD","LU0320764599.SGD","BK1610","LU0516423174.USD","LU0516423091.SGD","LU0572944931.SGD","BK1515","LU0456827905.SGD","LU0823426308.USD","LU1242518931.SGD","SG9999002562.SGD","LU0417516902.SGD","LU1688375341.USD","02269","LU0181495838.USD","LU1794554557.SGD","LU0516422440.USD","IE00B543WZ88.USD","LU0348783233.USD","LU0979878070.USD","LU2039709279.SGD","LU0043850808.USD","09939","LU0326950275.SGD","LU1242518857.USD","LU0051755006.USD","IE00B5MMRT66.SGD","BK1141","BK1589","09926","BK1576","BK1574"],"gpt_icon":0},{"id":"2445272217","title":"亚盛医药宣布已收到武田7500万美元股权投资款项","url":"https://stock-news.laohu8.com/highlight/detail?id=2445272217","media":"美通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445272217?lang=zh_cn&edition=full","pubTime":"2024-06-21 09:10","pubTimestamp":1718932200,"startTime":"0","endTime":"0","summary":"根据相关协议条款,亚盛医药已以每股认购股份 24.09850 港元的股份购买价向武田成功配发总共 24,307,322 股认购股份。截至目前,公司共有4个在研新药获得16项FDA和1项欧盟孤儿药资格认定,2项FDA快速通道资格以及2项FDA儿童罕见病资格认证。亚盛医药前瞻性声明 本文所作出的前瞻性陈述仅与本文作出该陈述当日的事件或资料有关。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4445233_ZH45233_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["CDE","BK4017","BK1574","06855","BK1161"],"gpt_icon":0},{"id":"2445470271","title":"【港股通】亚盛医药(06855)完成向Takeda International配发及发行2430.73万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2445470271","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445470271?lang=zh_cn&edition=full","pubTime":"2024-06-21 08:52","pubTimestamp":1718931138,"startTime":"0","endTime":"0","summary":"金吾财讯 | 亚盛医药(06855)宣布,所有股份认购先决条件已获达成及交割已于2024年6月20日(交易时段后)进行。公司已根据证券购买协议的条款及条件按每股认购股份24.09850港元(相当于约3.08549美元)的股份购买价向Takeda International成功配发及发行合共2430.7322万股认购股份。股份认购事项所得款项总额为7500万美元(相当于约5.86亿港元),而股份认购事项所得款项净额(扣除所有适用成本及开支后)约为7300万美元(相当于约5.7亿港元)。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/OWRlOWUwM2UzYzc0YWVmOThhNzQ1ZDFlMmFkZGIzYjY4MTQyOTUwNzU2MTA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/OWRlOWUwM2UzYzc0YWVmOThhNzQ1ZDFlMmFkZGIzYjY4MTQyOTUwNzU2MTA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1939042","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","HSTECH","HSCEI","YANG","07226","BK1574","06855","159938","BK1161","09939"],"gpt_icon":0},{"id":"2445278935","title":"亚盛医药-B(06855)完成向Takeda International发行合共约2430.73万股认购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2445278935","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445278935?lang=zh_cn&edition=full","pubTime":"2024-06-21 07:04","pubTimestamp":1718924648,"startTime":"0","endTime":"0","summary":"智通财经APP讯,亚盛医药-B(06855)公布,所有股份认购先决条件已获达成及交割已于2024年6月20日(交易时段后)进行。公司已根据证券购买协议的条款及条件按每股认购股份 24.09850港元(相当于约3.08549美元)的股份购买价向Takeda International成功配发及发行合共约2430.73万股认购股份,占扩大后股本约7.73%。股份认购事项所得款项总额为7500万美元,净筹约7300万美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1138357.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","159938","09939","BK1515","BK1574","BK1161"],"gpt_icon":0},{"id":"2444589982","title":"拆解国产小分子BD第一案","url":"https://stock-news.laohu8.com/highlight/detail?id=2444589982","media":"钛媒体APP","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444589982?lang=zh_cn&edition=full","pubTime":"2024-06-20 11:27","pubTimestamp":1718854032,"startTime":"0","endTime":"0","summary":"总计13亿美元的金额,创下了国产小分子药物对外BD的新纪录。这可能预示着国产小分子药物的崛起。这也表明,亚盛医药此前被市场质疑的流动性危机已经彻底解除。尽管亚盛医药的临床数据和BD交易条款已经证明了耐立克的价值,但武田制药成为其重要股东,更是进一步证实了耐立克的价值。把对手变为队友背后亚盛医药此次BD的另一大亮点,是合作伙伴武田制药本身。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406201131489f50ccef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406201131489f50ccef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06855","BK1161","BK1574","BK1515","09939","TAK"],"gpt_icon":0},{"id":"2444423762","title":"亚盛医药-B盘中异动 急速下跌5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2444423762","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444423762?lang=zh_cn&edition=full","pubTime":"2024-06-20 10:54","pubTimestamp":1718852066,"startTime":"0","endTime":"0","summary":"2024年06月20日早盘10时54分,亚盛医药-B股票出现异动,股价快速下跌5.11%。亚盛医药-B股票所在的生物技术行业中,整体涨幅为0.01%。消息层面,截至10时54分,亚盛医药-B股票正面舆情新闻比例3.7%。这并非亚盛医药第一次将奥雷巴替尼的权益对外授权。值得一提的是,在公告发布前,亚盛医药股价“提前”大涨,引发部分投资者质疑其有内幕交易之嫌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240620105426aef5c048&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240620105426aef5c048&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06855","BK1161","BK1574","BK1515","09939"],"gpt_icon":0},{"id":"2444548230","title":"亚盛医药-B(06855)股价下跌5.114%,现价港币$25.05","url":"https://stock-news.laohu8.com/highlight/detail?id=2444548230","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444548230?lang=zh_cn&edition=full","pubTime":"2024-06-20 10:54","pubTimestamp":1718852040,"startTime":"0","endTime":"0","summary":"[下跌股]亚盛医药-B(06855) 股价在上午10:54比前收市价下跌5.114%,现股价为港币$25.05。至目前为止,今日最高价为$26.5,而最低价为$25.05。总成交量为100.358万股,总成交金额为港币$2.571千万。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152743541_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152743541_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD240620517/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1515","159938","06855","BK1161","09939","BK1574"],"gpt_icon":0},{"id":"2444440749","title":"亚盛医药-B06月19日主力资金流入226万元 连续5日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2444440749","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444440749?lang=zh_cn&edition=full","pubTime":"2024-06-19 16:16","pubTimestamp":1718784972,"startTime":"0","endTime":"0","summary":"06月19日, 亚盛医药-B股价跌0.19%,报收26.40元,成交金额5040万元,换手率0.66%,振幅5.29%,量比0.40。亚盛医药-B今日主力资金净流入226万元,连续5日净流入,上一交易日主力净流入974万元,今日环比减少76.80%。近一年数据显示,该股主力连续5日净流入后,次日上涨概率为33.33%,平均涨幅为5.35%。该股近5个交易日上涨36.76%,主力资金累计净流入2804万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流入1626万元,其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061916164595c1157f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061916164595c1157f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06855","09939","BK1574","BK1515"],"gpt_icon":0},{"id":"2444105396","title":"【券商聚焦】东吴证券首予亚盛医药(06855)买入”评级 指奥雷巴替尼授权落地 全球创新步入收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2444105396","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444105396?lang=zh_cn&edition=full","pubTime":"2024-06-18 16:32","pubTimestamp":1718699573,"startTime":"0","endTime":"0","summary":"金吾财讯 | 东吴证券表示,亚盛医药 与武田就第三代BCR-ABL抑制剂奥雷巴替尼全球许可签署独家选择权协议,将奥雷巴替尼除中国之外的全球权利许可给武田,将获得①1亿美元不可退的选择权付款;②未来两年内有望获得选择权行使费,加上分阶段的里程碑付款总计12亿美元;③双位数的销售分成;④武田7500万美元股权投资。考虑公司收入增长较快,海外市场潜力较大,首次覆盖给予“买入”评级。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/YjQxYWY4NjkyMTU2YjM4ZTVhNGFhMzYzNjE2NzgxMDU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/YjQxYWY4NjkyMTU2YjM4ZTVhNGFhMzYzNjE2NzgxMDU=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1938858","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","159938","601555","06855"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascentagepharma.com","stockEarnings":[{"period":"1week","weight":0.081},{"period":"1month","weight":0.4364},{"period":"3month","weight":0.6576},{"period":"6month","weight":0.034},{"period":"1year","weight":0.2102},{"period":"ytd","weight":0.0018}],"compareEarnings":[{"period":"1week","weight":0.0176},{"period":"1month","weight":-0.0225},{"period":"3month","weight":0.078},{"period":"6month","weight":0.0903},{"period":"1year","weight":-0.0566},{"period":"ytd","weight":0.0575}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"亚盛医药集团是一家主要从事开发癌症、乙型肝炎病毒及若干衰老相关疾病的创新微型疗法的投资控股公司。该公司拥有自主研发的蛋白-蛋白相互作用靶向药物设计平台。该公司的主要产品包括下一代激酶抑制剂HQP1351,细胞凋亡靶向药物APG-1252、 APG2575、APG-115等。该公司于国内市场及美国等海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.061697},{"month":2,"riseRate":0.2,"avgChangeRate":-0.06377},{"month":3,"riseRate":0,"avgChangeRate":-0.152214},{"month":4,"riseRate":0.8,"avgChangeRate":0.111517},{"month":5,"riseRate":0.4,"avgChangeRate":0.061168},{"month":6,"riseRate":0.8,"avgChangeRate":0.262196},{"month":7,"riseRate":0.4,"avgChangeRate":-0.081057},{"month":8,"riseRate":0.75,"avgChangeRate":-0.014666},{"month":9,"riseRate":0,"avgChangeRate":-0.167512},{"month":10,"riseRate":0.5,"avgChangeRate":0.082137},{"month":11,"riseRate":0.6,"avgChangeRate":0.093711},{"month":12,"riseRate":0.6,"avgChangeRate":0.09133}],"exchange":"SEHK","name":"亚盛医药-B","nameEN":"ASCENTAGE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚盛医药-B(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚盛医药-B(06855)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚盛医药-B,06855,亚盛医药-B股票,亚盛医药-B股票老虎,亚盛医药-B股票老虎国际,亚盛医药-B行情,亚盛医药-B股票行情,亚盛医药-B股价,亚盛医药-B股市,亚盛医药-B股票价格,亚盛医药-B股票交易,亚盛医药-B股票购买,亚盛医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚盛医药-B(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚盛医药-B(06855)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}